These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12534284)

  • 1. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.
    Stoll V; Stewart KD; Maring CJ; Muchmore S; Giranda V; Gu YG; Wang G; Chen Y; Sun M; Zhao C; Kennedy AL; Madigan DL; Xu Y; Saldivar A; Kati W; Laver G; Sowin T; Sham HL; Greer J; Kempf D
    Biochemistry; 2003 Jan; 42(3):718-27. PubMed ID: 12534284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.
    Maring CJ; Stoll VS; Zhao C; Sun M; Krueger AC; Stewart KD; Madigan DL; Kati WM; Xu Y; Carrick RJ; Montgomery DA; Kempf-Grote A; Marsh KC; Molla A; Steffy KR; Sham HL; Laver WG; Gu YG; Kempf DJ; Kohlbrenner WE
    J Med Chem; 2005 Jun; 48(12):3980-90. PubMed ID: 15943472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site.
    Finley JB; Atigadda VR; Duarte F; Zhao JJ; Brouillette WJ; Air GM; Luo M
    J Mol Biol; 1999 Nov; 293(5):1107-19. PubMed ID: 10547289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors.
    Kim CU; Lew W; Williams MA; Wu H; Zhang L; Chen X; Escarpe PA; Mendel DB; Laver WG; Stevens RC
    J Med Chem; 1998 Jul; 41(14):2451-60. PubMed ID: 9651151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
    Mitrasinovic PM
    Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors.
    Zhang J; Wang Q; Fang H; Xu W; Liu A; Du G
    Bioorg Med Chem; 2007 Apr; 15(7):2749-58. PubMed ID: 17287121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent.
    Atigadda VR; Brouillette WJ; Duarte F; Ali SM; Babu YS; Bantia S; Chand P; Chu N; Montgomery JA; Walsh DA; Sudbeck EA; Finley J; Luo M; Air GM; Laver GW
    J Med Chem; 1999 Jul; 42(13):2332-43. PubMed ID: 10395473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives.
    Chand P; Babu YS; Bantia S; Rowland S; Dehghani A; Kotian PL; Hutchison TL; Ali S; Brouillette W; El-Kattan Y; Lin TH
    J Med Chem; 2004 Apr; 47(8):1919-29. PubMed ID: 15055992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors.
    Zhang J; Wang Q; Fang H; Xu W; Liu A; Du G
    Bioorg Med Chem; 2008 Apr; 16(7):3839-47. PubMed ID: 18304821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
    Chand P; Babu YS; Bantia S; Chu N; Cole LB; Kotian PL; Laver WG; Montgomery JA; Pathak VP; Petty SL; Shrout DP; Walsh DA; Walsh GM
    J Med Chem; 1997 Dec; 40(25):4030-52. PubMed ID: 9406595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
    Du QS; Wang SQ; Chou KC
    Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity.
    Grembecka J; Mucha A; Cierpicki T; Kafarski P
    J Med Chem; 2003 Jun; 46(13):2641-55. PubMed ID: 12801228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors.
    Lou J; Yang X; Rao Z; Qi W; Li J; Wang H; Li Y; Li J; Wang Z; Hu X; Liu P; Hong X
    Eur J Med Chem; 2014 Aug; 83():466-73. PubMed ID: 24992074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target.
    Hochgürtel M; Biesinger R; Kroth H; Piecha D; Hofmann MW; Krause S; Schaaf O; Nicolau C; Eliseev AV
    J Med Chem; 2003 Jan; 46(3):356-8. PubMed ID: 12540234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
    Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin TH; Hutchison TL; Babu YS; Bantia S; Elliott AJ; Montgomery JA
    J Med Chem; 2001 Dec; 44(25):4379-92. PubMed ID: 11728184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid.
    Bossart-Whitaker P; Carson M; Babu YS; Smith CD; Laver WG; Air GM
    J Mol Biol; 1993 Aug; 232(4):1069-83. PubMed ID: 8371267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase.
    Jedrzejas MJ; Singh S; Brouillette WJ; Air GM; Luo M
    Proteins; 1995 Oct; 23(2):264-77. PubMed ID: 8592707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
    Babu YS; Chand P; Bantia S; Kotian P; Dehghani A; El-Kattan Y; Lin TH; Hutchison TL; Elliott AJ; Parker CD; Ananth SL; Horn LL; Laver GW; Montgomery JA
    J Med Chem; 2000 Sep; 43(19):3482-6. PubMed ID: 11000002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.